Ubrogepant for the Treatment of Migraine
Ubrogepant for the Treatment of Migraine
About this item
Full title
Ubrogepant for the Treatment of Migraine
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2019-12, Vol.381 (23), p.2230-2241
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
A higher percentage of participants who received the calcitonin gene–related peptide receptor antagonist ubrogepant had freedom from migraine pain and absence of the most bothersome migraine-associated symptom at 2 hours than participants who received placebo.
Alternative Titles
Full title
Ubrogepant for the Treatment of Migraine
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2322140149
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2322140149
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1813049
